Mergers and acquisitions
The latest mergers and acquisitions news from across all sectors of the chemical and pharmaceutical industries, from the Royal Society of Chemistry's magazine, Chemistry World
-
Business
Novo Holdings to buy contract manufacturer Catalent for $16.5 billion
Parent firm will then sell on three manufacturing sites to Novo Nordisk to boost capacity for diabetes and weight loss drugs
-
Business
Illumina to give up Grail as competition appeals fail
Sequencing giant will sell off its former spin-out in accordance with regulator orders
-
Business
Pharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
Business
Chemicals roundup 2023
Chemical companies entered cost-cutting mode in a year dominated by overcapacity and slow demand
-
Business
Danaher completes $5.7 billion Abcam acquisition
Deal proceeded despite significant opposition from founder and ex-chief Jonathan Milner
-
Business
Building the support infrastructure we wish we’d had
Harry Destecroix of Science Creates is the 2023 Chemistry World Entrepreneur of the Year
-
Business
ExxonMobil to buy Pioneer for US shale oil dominance
$59 billion deal sees Exxon double its shale oil and gas production
-
Business
Biogen to cut 1000 more jobs by 2025
Biotech giant has also agreed to buy Reata Pharmaceuticals for $7.3 billion
-
Business
Illumina’s Grail quest results in epic fine
EU and US competition authorities object to firms completing merger without approval
-
Business
US trade regulator sues to block Amgen–Horizon merger
Federal Trade Commission has concerns that union will allow Amgen to stifle potential competition for Horizon’s drugs
-
Business
Pfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
Business
Chemicals industry roundup 2022
Russia’s invation of Ukraine mounted further pressure onto already strained supply chains
-
Business
Pharmaceuticals roundup 2022
Following the huge success of vaccines and treatments for covid-19, companies are upping their investment in R&D and dealmaking
-
Business
Haleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
Business
DSM and Firmenich to merge
Flavour and fragrance-focused Firmenich complements DSM’s transition away from traditional chemicals
-
Business
Pharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
Business
Morphosys agrees to buy cancer epigenetics specialist Constellation
$1.7bn deal will be funded by selling rights to royalties on existing drugs
-
Business
Shell to sell US refinery stake to Mexican state-owned petroleum company
Pemex will take full control of Deer Park refinery, as Mexico’s president moves to gain energy independence
-
Business
Government clears merger of SinoChem and ChemChina
China’s chemicals giants will unite under a state-run holding company
-
Business
Biggest venture yet of any pharma company into cannabis
Jazz Pharmaceuticals buys cannabinoid therapeutic firm for $7.2 billion, inheriting first plant-derived cannabinoid medicine ever approved by FDA